MENU
+Compare
GIKLY
Stock ticker: OTC
AS OF
Nov 12 closing price
Price
$6.16
Change
+$0.15 (+2.50%)
Capitalization
7.59B

GIKLY stock forecast, quote, news & analysis

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins... Show more

GIKLY
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. GIKLY showed earnings on November 04, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for GIKLY with price predictions
Nov 12, 2025

GIKLY's Indicator enters downward trend

The Aroon Indicator for GIKLY entered a downward trend on November 12, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 232 similar instances where the Aroon Indicator formed such a pattern. In of the 232 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GIKLY as a result. In of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GIKLY turned negative on November 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

Bullish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.396) is normal, around the industry mean (9.612). P/E Ratio (19.476) is within average values for comparable stocks, (23.835). Projected Growth (PEG Ratio) (0.236) is also within normal values, averaging (2.037). Dividend Yield (0.014) settles around the average of (0.028) among similar stocks. P/S Ratio (0.962) is also within normal values, averaging (3.560).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GIKLY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GIKLY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

A.I.Advisor
published Dividends

GIKLY paid dividends on August 20, 2025

Grifols Sa GIKLY Stock Dividends
А dividend of $0.09 per share was paid with a record date of August 20, 2025, and an ex-dividend date of August 12, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 98.13B. The market cap for tickers in the group ranges from 72.83K to 910.93B. LLY holds the highest valuation in this group at 910.93B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 3%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 19%. OGN experienced the highest price growth at 21%, while GIKLY experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -9%. For the same stocks of the Industry, the average monthly volume growth was 72% and the average quarterly volume growth was 42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 63
Price Growth Rating: 51
SMR Rating: 62
Profit Risk Rating: 76
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
GIKLY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Avinguda de la Generalitat, 152
Phone
+34 935712200
Employees
23744
Web
https://www.grifols.com